RecruitingNCT06979869

Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Esophageal Carcinoma


Sponsor

Xijing Hospital

Enrollment

300 participants

Start Date

May 26, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The primary objective is to determine whether pretreatment-to-posttreatment changes in circulating multigene methylation levels correlate with objective response rates (ORR) assessed by contrast-enhanced CT/MRI and levels of serum tumor markers. Secondary endpoints include: (a) time-dependent association between methylation fluctuation patterns and progression-free survival (PFS), (b) comparative diagnostic accuracy of methylation indices versus conventional biomarkers, and (c) feasibility of using methylation thresholds to guide adaptive therapy modification.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria1

  • Age at initial diagnosis: 18-75 years (inclusive) Confirmed diagnosis: Histologically proven esophageal carcinoma with complete medical records, including (a) definitive pathological diagnosis report, (b) TNM staging per AJCC 8th edition criteria Cancer history: No prior malignancies at other anatomical sites (excluding cured non-melanoma skin cancers/carcinoma in situ) Metastasis status: Radiologically confirmed absence of distant metastases in liver, lungs, or other organs via contrast-enhanced CT/MRI and whole-body bone scan within 4 weeks before enrollment Treatment-naïve status: No previous exposure to (i) esophageal resection surgery, (ii) systemic chemotherapy, (iii) thoracic radiation therapy (\>10 Gy), or (iv) PD-1/PD-L1 immune checkpoint inhibitors

Exclusion Criteria1

  • Life expectancy \<6 months (as assessed by ECOG score ≥4 or Palliative Performance Scale ≤30%) Cognitive/psychiatric conditions: a. Legally incapacitated individuals without legal guardians, b. Active psychotic disorders (e.g., schizophrenia, bipolar disorder) or dementia (MMSE score \<24) Investigator-determined exclusions

Interventions

OTHERMulti-gene methylation testing

Undergo multi-gene methylation testing in blood during follow-up

OTHERMulti-gene methylation testing

Undergo multi-gene methylation testing in blood during follow-up

OTHERMulti-gene methylation testing

Undergo multi-gene methylation testing in blood during follow-up

OTHERMulti-gene methylation testing

Undergo multi-gene methylation testing in blood during follow-up


Locations(9)

Gansu Wuwei Cancer Hospital

Wuwei, Gansu, China

Cancer Hospital Affiliated to Shantou University Medical College

Shantou, Guangdong, China

Zhaoqing Gaoyao District People's Hospital

Zhaoqing, Guangdong, China

Henan Cancer Hospital

Zhengzhou, Henan, China

Tangdu Hospital

Xi'an, Shaanxi, China

Xijing Hospital

Xi'an, Shaanxi, China

The First Affiliated Hospital of Yan'an University

Yan’an, Shaanxi, China

The First Affiliated Hospital of Shanxi Medical University

Taiyuan, Shanxi, China

General Hospital of Western Theater Command, People's Liberation Army (PLA)

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06979869


Related Trials